DekaBank Deutsche Girozentrale
EIGR

DekaBank Deutsche Girozentrale’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-27
Closed -$17K – 1108
2015
Q4 		$17K Hold
27
– – ﹤0.01% 1048
2015
Q3 		$13K Buy
27
+1
+4% +$530 ﹤0.01% 1107
2015
Q2 		$14K Sell
26
-3
-10% -$8.3K ﹤0.01% 1149
2015
Q1 		$248K Buy
+29
New +$254K ﹤0.01% 860

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DekaBank Deutsche Girozentrale's EIGR Position: Q1 2016 in Review

DekaBank Deutsche Girozentrale sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2016, closing a stake of 27 shares — an estimated $17K sold.

DekaBank Deutsche Girozentrale first reported a position in EIGR in Q1 2015 and held it in 4 quarters. The position peaked at $248K in Q1 2015. 30 funds tracked by Wall St. Rank hold EIGR as of Q1 2016.

  • DekaBank Deutsche Girozentrale reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 27 Eiger BioPharmaceuticals, Inc. shares in Q1 2016, an estimated $17K.
  • DekaBank Deutsche Girozentrale first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Eiger BioPharmaceuticals, Inc. position peaked at $248K in Q1 2015.
  • 30 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2016.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2016, filed 13 May 2016.